Revlimid, Imnovid combos receive EU approval

pharmatimes | May 17, 2019

The European Commission has approved two of Celgene’s combination regimens involving Revlimid (lenalidomide) and Imnovid (pomalidomide). The first, Revlimid in combination with bortezomib and dexamethasone (RVd) is for the indication of adult patients with previously untreated multiple myeloma who are not eligible for transplant. The second combo is Imnovid in combination with bortezomib and dexamethasone (PVd), in adult patients with multiple myeloma, who have received at least one prior treatment regimen including Revlimid. The approval for the Revlimid triplet (RVd) was supported by data from SWOG S0777 phase III trial evaluating the combination, RVd, in adult patients with previously untreated multiple myeloma. The approval of the Imnovid triplet (PVd) was supported by data from OPTIMISMM phase III trial to evaluate an Imnovid-based triplet regimen in patients who were all previously treated with Revlimid.

Spotlight

The current Ebola outbreak in the Democratic Republic of Congo is the largest ever recorded in that country, and it's proving especially difficult to curtail. Here, Doctors Without Borders/Médecins Sans Frontières (MSF) tropical medicine advisor Tomas Jensen describes the challenges MSF teams face as they fight the spread of the disease, including the active conflict in the region.


Other News
BUSINESS INSIGHTS

Ellipses Pharma and SunRock Biopharma Enter Into a Licensing Agreement for a First-in-class Bifunctional HER3:TRAIL Fusion Protein

SunRock Biopharma S.L | May 26, 2022

SunRock Biopharma S.L. a biopharmaceutical company that is developing a portfolio of innovative bispecific antibodies to treat incurable cancer, and Ellipses Pharma Limited a global drug development company focused on accelerating the development of new oncology treatments, announce that they have entered into an exclusive licensing agreement for SRB22, a fully human bifunctional HER3:TRAIL fusion protein, which going forward will be known as EP0017. Under the agreement, Ellipses has been granted global rights to develop and commercialise EP0017 and will assume the full cost and responsibility for the remaining pre-clinical and clinical development of the compound. In line with its strategy, Ellipses intends to out licence EP0017 for commercialisation if it proves safe and effective in clinical trials. SunRock will continue to be involved in the development of EP0017 to ensure efficient translational activities through a service agreement with Ellipses. If Ellipses out-licences EP0017, SunRock will also receive milestone payments and royalties. EP0017 is a first-in-class bifunctional fusion protein with a dual mechanism of action. It selectively targets HER3, which is overexpressed in several different tumour types, and additionally, binds to the tumour death receptors DR4 and DR5, inducing tumour cell death. Promising data has been generated in a range of preclinical models that demonstrate the potential of EP0017. Laureano Simón, Ph.D., CEO of SunRock Biopharma, said “The agreement with Ellipses will speed up the development of EP0017, moving this potentially life-changing asset towards the clinic and then hopefully towards cancer patients who desperately need novel approaches to fight invasive tumours.” Rajan Jethwa, MD, CEO of Ellipses Pharma “Our mission is to rapidly develop innovative cancer therapies, to get these therapies into the clinic as quickly as possible and potentially save more lives. We are excited about the opportunity to progress the development of this promising asset and look forward to working with SunRock to expedite the preclinical work.” About SunRock Biopharma S.L. Since its inception in 2014, SunRock has developed a comprehensive pipeline of seven therapeutic antibodies, bispecific antibodies and fusion proteins with proven therapeutic effects against several types of tumours that currently lack a treatment. The innovative spirit of SunRock defines the development of all its molecules, that are the result of a disruptive technological platform that has led to pioneer therapies with an innovative format, including first-in-class bispecific antibodies and fusion proteins that target both novel and well-known therapeutic targets. SunRock’s project portfolio is generating great expectations among patient associations, major hospitals, and biopharmaceutical companies. The Government of Galicia participates in SunRock through the Galicia Innova Tech Fund, FICC. About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer medicines and treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection with an uninterrupted funding flow to minimize the time it takes to advance lead products through clinical trials and reach patients.

Read More

BUSINESS INSIGHTS

Avidien Technologies Receives $4M Investment from BroadOak Capital Partners

Avidien Technologies | February 02, 2022

Avidien announced a new financing round of $4M from BroadOak Capital Partners. The investment will help Avidien expand its product roadmap, scale commercial production, and better serve research and pharmaceutical clients. "The partnership with BroadOak is exciting and ushers in the next phase for Avidien by creating the opportunity to quickly scale up the business with investments in new products, sales, marketing, and manufacturing." Avidien CEO and Founder Rich Cote Avidien's flagship product, the microPro 300, provides precision semi-automated 96 and 384 channel pipetting to hundreds of biotech, medical testing, and research laboratories worldwide. The compact and portable liquid handling platform has built a loyal customer base thanks to its innovative design, intuitive interface, and industry-leading capabilities. The microPro 300 fills gaps in automation workflows by streamlining repetitive pipetting tasks and ensuring accurate, repeatable liquid transfers. BroadOak Capital Partners is a life sciences focused financial institution with a track record of supporting companies at the forefront of major industry trends. "Aviden's affordable pipette automation platform sets a new standard for common research methods and is at the cutting edge of laboratory automation technology. We're proud to partner with the Avidien team to help them achieve even greater growth," said Bryan Poltilove, Operating Partner at BroadOak Capital Partners. Mr. Poltilove is also joining Avidien's Board of Directors to guide the company's next phase of business expansion. About Avidien Technologies Avidien Technologies is a Massachusetts based company that manufactures innovative and precision liquid handling solutions that are deployed in life science labs around the world. About BroadOak Capital Partners BroadOak Capital Partners, with headquarters in Washington, DC and San Francisco, is a life sciences focused financial institution that provides direct investment and investment banking services to companies in the research tools and consumables, diagnostics, biopharma services, and adjacent markets. BroadOak has led or participated in investments in more than 50 companies across multiple funds and investment vehicles.

Read More

PHARMACY MARKET

FemTec Health Taps GeniusRx as Exclusive Online Pharmacy Partner for D2C Platform Awesome Woman

FemTec Health | February 19, 2022

FemTec Health, the leading health and beauty sciences company, announced an exclusive partnership with online pharmacy company GeniusRx that will provide Awesome Woman members access to on-demand, door-to-door medication delivery. Launching later this month, Awesome Woman is FemTec Health's consumer brand that will provide personalized health and wellness services along with products that are meaningful and effective to women at all life stages. Areas of focus include menopause, fertility, wellness and prevention, reproductive care, sexual wellness, mental health, chronic care, and beyond. GeniusRx will offer Awesome Woman members access to medications at the best price. "Women are ready for a new experience. We believe that a woman deserves a single trusted source that unifies and personalizes her healthcare. It's time for the healthcare industry to transform into an end-to-end personalized experience for every woman, at every stage of her life," said FemTec Health Chief Medical Officer Dr. Laura Clapper. FemTec Health was founded in May 2020 and publicly launched in October 2021 by serial entrepreneur Dr. Kimon Angelides who serves as Executive Chairman and Interim CEO of the company. Previously, Dr. Angelides founded several renowned digital health tech companies including Diabetes America, Vivante Health and EosHealth which was renamed Livongo. GeniusRx was launched in 2020 by telemedicine industry veteran Randy Parker. Both founders believe in solving inefficiencies to fix an expensive, fragmented healthcare experience. "We're excited to partner with GeniusRx to include pharmacy into the Awesome Woman offering of integrated personalized products and services to support women having the information, power and control to make their own health and wellness decisions from home," said Dr. Angelides. "With Awesome Woman's telehealth services and GeniusRx's competitive pricing and door-to-door accessibility, we remove the stress associated with having to go to the doctor and then to the pharmacy. This is the first of many partnerships we will be announcing to reinvent women's healthcare." "At GeniusRx, we take a patient-centered approach to help people achieve better health. We do it by providing convenient home delivery of medications and easy access to pharmacists who can provide optimal care and guidance around medications. We want to support women on their health journey and are excited to partner with FemTec on this mission to empower their health and wellness,'' said Randy Parker, CEO of GeniusRx. About FemTec Health Founded in May 2020 by Dr. Kimon Angelides and publicly launched in October 2021, FemTec Health is the leading Health and Beauty Sciences Company focused on using technology and data to transform the total healthcare experience for women in every stage of their life cycle. FemTec Health's mission is to revolutionize women's healthcare by using state-of-the-art genomics, predictive intelligence, and digital technologies to create an experience that is unified, coordinated, and provides personalized services and products based on every woman's unique needs. In addition to FemTec Health's direct to consumer offerings, the company also works with employers, health plans, and providers. With offices in New York, Houston, San Diego, London, Barcelona, Athens & Shanghai, FemTec Health currently has over 150 employees and is growing rapidly. Investors, capital and shareholders include Unilever Ventures, e.Ventures, Viking Global, Trinity Capital, and Longmont Capital with more than $38M raised to date. About GeniusRx GeniusRx is a full-service digital pharmacy designed to make access to medicine simple, intuitive, and personal. Utilizing technology to disrupt pricing, driving adherence, and deliver convenient & affordable pharmacy products and services, GeniusRx simplifies pharmacy to improve patient outcomes. As a US based pharmacy licensed in 49 states, GeniusRx is able to offer quality medications, secure purchases, and deliver nationwide. All of that coupled with real-time pharmacy communications and support, all accessible through our health & wellness "hub". GeniusRx's advanced pharmacy dispensing and fulfillment center users the latest in pharmacy automation, intelligence, and technology to provide patients with simple, safe, affordable, and personalized patient care services and medications.

Read More

PHARMA TECH

iXensor Receives Strategic Investment from Rohto Pharmaceutical with A Separate Technology Licensing Agreement

iXensor | April 28, 2022

iXensor, the pioneer of mobile health, announced that Rohto Pharmaceutical Co., Ltd, a multinational pharmaceutical corporation headquartered in Japan, has become the new strategic partner and shareholder. iXensor received Rohto Pharmaceutical's strategic investment to expand its mobile health business globally and accelerate its PixoTech® platform licensing business. Building on this strategic partnership, Rohto Pharmaceutical will deploy iXensor's patented PixoTech® technology to digitize its new products through a separate technology licensing and joint development agreement, thereby providing Rohto Pharmaceutical's consumers with innovative self-testing portfolios including women's health and infectious diseases in Japan market. iXensor's first product, PixoTest® Glucose Monitoring System, developed based on its PixoTech® platform, is the world's first US FDA-approved smartphone camera-based blood test dated in 2017. The PixoTech®, currently protected by more than 70 international patents, is iXensor's core technology platform that transforms smartphones into in vitro diagnostic instruments for biomedical analysis in point-of-care testing and self-testing. PixoTech® controls smartphones' camera sensing modules and screen lighting emissions with multiple wavelengths to analyze all types of immunoassay and enzymatic tests through the proprietary algorithm. "By investing in iXensor, we can deepen our joint efforts on a series of new product developments, thus expanding our testing and diagnostic business through a wave of digital transformation. As the first step, we will receive a technical license for smartphone-based diagnostic devices and apps from iXensor to develop and sell innovative self-testing products." Mr. Hidetoshi Segi, Chief Strategy Officer of Rohto Pharmaceutical Dr. Carson Chen, CEO of iXensor, expressed, "This partnership represents the unlimited potential and technical advantage of the PixoTech® platform to transform smartphones into precision medical diagnostic devices. The licensing business of PixoTech® technology started shifting in as the new engine to drive iXensor's growth." In the post-pandemic era, iXensor endeavors to accelerate the growth of the at-home self-testing market and empower the evolution of the digital health ecosystem through licensing the PixoTech® technology. Thanks to that, PixoTech® can be flexibly applied to the digitalization of various lateral flow tests. In addition, it can shorten the lead time for IVD manufacturers venturing into the digital health business. It can also be applied to develop companion diagnostic or remote monitoring tools for pharmaceuticals to prove the efficacy of new classes of medications with actual test results collected from patients' smartphones with comfort at home. About Rohto Pharmaceutical Founded in 1899, Rohto Pharmaceutical is a renowned Japanese company that has successfully commercialized its research and development of consumer and pharmaceutical products worldwide. Rohto Pharmaceutical has established a robust product portfolio, including eye care, skincare, gastrointestinal medicines, and functional foods. Within the test drug business, the novel coronavirus antigen rapid test for medical institutions was launched in response to the global epidemic in addition to the existing pregnancy test, ovulation test, and flu rapid test products. About iXensor iXensor, the pioneer of mobile health, turns smartphones into lab-grade mobile medical diagnostics. In 2017, iXensor introduced the PixoTest® Blood Glucose Monitoring System as the world's first US FDA-approved smartphone camera-based blood test. Based on the PixoTech® platform, iXensor has ventured into at-home self-testing and clinical point-of-care diagnostics across infectious diseases, women's health, diabetes, and cardiovascular diseases.

Read More

Spotlight

The current Ebola outbreak in the Democratic Republic of Congo is the largest ever recorded in that country, and it's proving especially difficult to curtail. Here, Doctors Without Borders/Médecins Sans Frontières (MSF) tropical medicine advisor Tomas Jensen describes the challenges MSF teams face as they fight the spread of the disease, including the active conflict in the region.

Resources